Stockscreener 앱 받기
19.39
3.75%
0.70
시간 외 거래:
19.39
전일 마감가:
$18.69
열려 있는:
$19.06
하루 거래량:
1.31M
Relative Volume:
1.42
시가총액:
$2.18B
수익:
$14.09M
순이익/손실:
$-176.94M
주가수익비율:
-9.0186
EPS:
-2.15
순현금흐름:
$-141.24M
1주 성능:
+12.02%
1개월 성능:
-3.20%
6개월 성능:
+6.13%
1년 성능:
+2.81%
1일 변동 폭
$18.78
$20.08
1주일 범위
$16.95
$20.08
52주 변동 폭
$14.06
$27.29
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
명칭
Newamsterdam Pharma Company Nv
전화
35 206 2971
주소
GOOIMEER 2-35, NARRDEN
NAMS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
19.39 | 1.94B | 14.09M | -176.94M | -141.24M | -2.15 |
|
ONC
Beone Medicines Ltd Adr
|
258.27 | 26.01B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.85 | 114.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3499 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.98 | 6.29B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
484.93 | 63.90B | 14.09B | 4.50B | 2.96B | 39.28 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-04 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-05-15 | 개시 | TD Cowen | Buy |
| 2024-03-14 | 개시 | Scotiabank | Sector Outperform |
| 2024-01-18 | 개시 | Guggenheim | Buy |
| 2024-01-16 | 개시 | Piper Sandler | Overweight |
| 2023-10-30 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Newamsterdam Pharma Company Nv 주식(NAMS)의 최신 뉴스
Cantor Fitzgerald initiates overweight rating for NewAmsterdam Pharma stock - Investing.com
Cantor Fitzgerald Initiates NewAmsterdam Pharma Overweight With $42 Price Target - marketscreener.com
RBC Capital maintains outperform rating for NewAmsterdam Pharma stock By Investing.com - Investing.com South Africa
RBC Capital maintains outperform rating for NewAmsterdam Pharma stock - Investing.com India
Northern Trust Corp Takes $556,000 Position in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) Rating Increased to Hold at Wall Street Zen - Defense World
(NAMSW) Proactive Strategies - news.stocktradersdaily.com
Shareholders Will Probably Not Have Any Issues With NewAmsterdam Pharma Company N.V.'s (NASDAQ:NAMS) CEO Compensation - simplywall.st
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June - The Manila Times
NewAmsterdam Pharma CEO to Present at William Blair, Jefferies, and Goldman Sachs Healthcare Conferences - Stock Titan
NewAmsterdam Pharma (NASDAQ:NAMS) Given Consensus Recommendation of “Buy” by Analysts - Defense World
(NAMS) Technical Pivots with Risk Controls - news.stocktradersdaily.com
NewAmsterdam Pharma’s SWOT analysis: obicetrapib stock poised for cardiovascular market By Investing.com - Investing.com South Africa
NewAmsterdam Pharma’s SWOT analysis: obicetrapib stock poised for cardiovascular market - Investing.com Canada
35,657 Shares in NewAmsterdam Pharma (NASDAQ:NAMS) Purchased by BNP Paribas Financial Markets - Defense World
Financial Contrast: NewAmsterdam Pharma (NAMS) versus Its Rivals - Defense World
(NAMSW) Investment Analysis - news.stocktradersdaily.com
The Manufacturers Life Insurance Company Purchases New Position in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
Tower Research Capital LLC TRC Sells 6,485 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
Wall Street Analysts Predict a 132.5% Upside in NewAmsterdam Pharma Company N.V. (NAMS): Here's What You Should Know - MSN
NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference - GlobeNewswire
NewAmsterdam Pharma Showcases Non-Statin CVD Pipeline at Major RBC Healthcare Conference - Stock Titan
(NAMS) Proactive Strategies - news.stocktradersdaily.com
Analysts Have Been Trimming Their NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Price Target After Its Latest Report - simplywall.st
Barclays PLC Buys 9,117 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
Needham & Company LLC Issues Pessimistic Forecast for NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price - Defense World
NewAmsterdam Pharma Reports Q1 2025 Financial Results - TipRanks
NewAmsterdam Pharma Q1 Net Loss Narrows, Revenue Rises - marketscreener.com
NewAmsterdam Pharma Company NV reports results for the quarter ended March 31Earnings Summary - TradingView
NewAmsterdam Pharma Company N.V. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results - GlobeNewswire
Ratios Revealed: Decoding NewAmsterdam Pharma Company NV (NAMS)’s Financial Health - DWinneX
Earnings Flash (NAMS) NewAmsterdam Pharma Co. NV Reports Q1 Revenue $2.98M, vs. FactSet Est of $1.6M - marketscreener.com
Earnings Flash (NAMS) NewAmsterdam Pharma Co. NV Reports Q1 Revenue $3M, vs. FactSet Est of $1.6M - marketscreener.com
NewAmsterdam Pharma Q1 2025 Financial Results and Corporate Update - TradingView
Envestnet Asset Management Inc. Sells 8,738 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
NewAmsterdam Pharma Announces Late-Breaking Data from - GlobeNewswire
NewAmsterdam Pharma (NAMS) Reveals Promising Phase 3 Study Results for Obicetrapib | NAMS Stock News - GuruFocus
NewAmsterdam Pharma Presents Promising Phase 3 Trial Data - TipRanks
NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025 - marketscreener.com
Trend Tracker for (NAMS) - news.stocktradersdaily.com
Brokerages Set NewAmsterdam Pharma (NASDAQ:NAMS) PT at $43.33 - Defense World
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
NewAmsterdam Pharma Expands Clinical Team with 11 New Hires, Awards $4M in Equity Grants - Stock Titan
Examining NewAmsterdam Pharma Company NV (NAMS) stock is warranted - uspostnews.com
NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress - GlobeNewswire
Major Breakthrough: NewAmsterdam Reveals Multiple Phase 3 Trial Results for Novel Heart Drug - Stock Titan
Geode Capital Management LLC Raises Holdings in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
NewAmsterdam Pharma Company N.V. (NAMS): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside Potential - Insider Monkey
Legal & General Group Plc Acquires 4,556 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
Newamsterdam Pharma Company Nv (NAMS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.00%
0.54%
자본화:
|
볼륨(24시간):